Wright Moves More To Extremes With Tornier Purchase Agreement
This article was originally published in The Gray Sheet
Executive Summary
The all-stock transaction valued at around $3.3 billion will create a device and biologics company with a comprehensive focus on orthopedic extremities surgery. The firms expect cost synergies of $40 to $45 million.
You may also be interested in...
Stryker Goes Shoulder To Shoulder With Wright Medical In $4Bn Takeover
Stryker is acquiring rival Wright Medical in a $4bn deal catapulting the company to a top position in the trauma and extremities market. The agreement, announced on 4 November, is Stryker’s biggest acquisition this year.
Wright Place, Wright Time? Ortho Specialist's Focus Is Paying Off
In reinventing itself as a niche specialist in the orthopedic market, Wright Medical is putting efforts into maintaining leadership in the upper and lower extremities and building on its biologics strengths – a sales platform that was reinforced highly synergistically on the acquisition of Tornier. But for however long Wright Medical can remain independent, how does it balance value-based health care with strategic development plans?
Tornier Toes FTC Line With Lower-Extremity Sale To Integra
Integra is buying the U.S. rights to Tornier's Salto Talaris and Salto XT ankle replacement products and its Futura silastic toe replacement products for an undisclosed cash payment. The deal is intended to satisfy antitrust concerns in Wright Medical's pending purchase of Tornier and to strengthen Integra's position in the lower-extremity market.